Picking out gems from the weeds
It’s time for a pre-meeting preview as we head into the busy Fall cancer conference season.
First up is the IASLC organised World Conference on Lung Cancer (WCLC) being held in Toronto later this month.
We provide a review of some of the key abstracts and highlight some of the interesting topics to watch out for.
Updates will follow later once the data is presented as many of the abstracts are embargoed until the day of presentation.
To learn more from our latest analysis and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This week the Cancer Conference Coverage moves to the joint IASLC-AACR symposium on the Molecular Origins of Lung Cancer in San Diego. Having attended previous events (this is the third one they’ve hosted) and rather enjoyed them, this year I’m following it remotely.
What’s particularly nice about this type of specialist event is that they are especially useful for chatting informally with attendees and being able to ask a lot of questions that simply wouldn’t be feasible at larger meetings due to time and other constraints.
This review covers my thoughts on two immunotherapies, namely Merck’s anti-PD-1, which was previously presented at the World Lung Conference, plus a completely novel and very different approach that looks really quite exciting.
To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content.